Active, not recruitingPhase 1NCT03389802
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pediatric Brain Tumor Consortium
- Principal Investigator
- Ira DunkelMemorial Sloan Kettering Cancer Center
- Intervention
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients(biological)
- Enrollment
- 32 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2018 – 2026
Study locations (11)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Childrens National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States
- Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- St. Jude Children Research Hospital, Memphis, Tennessee, United States
- Baylor College of Medicine, Houston, Texas, United States
Collaborators
American Lebanese Syrian Associated Charities · Pyxis Oncology, Inc · Solving Kids' Cancer · Ty Louis Campbell Foundation · A Kids' Brain Tumor Cure Foundation · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03389802 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland